Results · Apr-Jun 2026
Gujarat Inject (Kerala) Q1 FY27 results
Sales grew 414% to ₹12.5 crore from ₹2.4 crore in Apr-Jun 2025.
Operating profit grew 1619% to ₹1.7 crore, an operating margin of 13.6% (up 9.5 points from a year ago).
Net profit grew 1603% to ₹1.3 crore from ₹0.07 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −59%, net profit −23%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 12.5 | 2.4 | +414% |
| Operating profit (EBITDA) | 1.7 | 0.1 | +1619% |
| Operating margin | 13.6% | 4.1% | +9.5 pts |
| Net profit | 1.3 | 0.1 | +1603% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.